Alternative splicing of pre-mRNAs provides a powerful mechanism to augment the protein repertoire encoded by metazoan genomes. It is estimated that 74% of all multiexonic human genes are alternatively spliced (36) . Moreover, alternative splicing is becoming increasingly relevant to a variety of human diseases, including cancer (60, 85) . These observations justify current efforts devoted at uncovering the basic principles of alternative splicing control. Many studies have provided valuable insights into the roles of specific elements and factors in splicing modulation (7, 58, 84) . Proteins that bind to specific sequence elements to affect splice site selection include SR proteins, hnRNP proteins, and other related RNA binding proteins such as TIA-1, ETR-3, Raver-1, and Sam68 (16, 29, 35, 54, 59, 76) . Many of these proteins can be modified posttranslationally, and some of the modifications, like phosphorylation, can affect their localization and activity (59, 82) .
Although we expect that the coupling between signal transduction events and alternative splicing decisions will represent a major network of regulation, very little is known about how splicing is coordinated by a variety of effectors to attune cells to specific environmental demands and stresses. Possibly the first system describing a link between signal transduction and splicing involved the cell surface molecule CD44, in which exon v5 inclusion was stimulated following activation of the protein kinase C (PKC) or extracellular signal-regulated kinase, as part of the Ras signaling pathway (41) . It was later shown that this occurred through stimulation of Sam68 binding to exon v5 after its phosphorylation (59) . Interestingly, the Ras-induced production of CD44 receptors made from the exon v6-containing mRNA in turn enhances Ras activation to enforce cell cycle progression (17) .
A signaling pathway also triggered by Ras and PKC promotes the skipping of exons in the transmembrane protein phosphatase CD45 pre-mRNA (53, 73) . Because hnRNP L is essential for the repression of several CD45-regulated exons (74) , the aim of this signaling route may be to enforce the activity of hnRNP L or to repress the activity of proteins bound to nearby enhancers (49, 88) . Recent progress has also been made in identifying sequences and factors that control alternative splicing decisions of the NMDA receptor upon depolarization or constitutive CaM kinase IV expression (3) . The instruction to skip exon C1 is relayed by a variety of elements, some bound by hnRNP A1 (2, 45) . On the other hand, the cellular localization of hnRNP A1 is controlled by the MEK 3/6 -p38 pathway (89) . SR proteins have been implicated in multiple cases of alternative splicing control, and they are extensively phosphorylated. Although SR proteins can be phosphorylated by SRPK1, SRPK2, Clk/Sty, and topoisomerase I (27) , the signaling pathways that converge on these kinases remain unclear. Recently, contributions to splicing control by signaling pathways involving AKT kinase, phosphatidylinositol 3-kinase, and Jun N-terminal protein kinase have also been documented (8, 9, 24, 64, 65, 67) .
Apoptosis, or programmed cell death, represents an important mechanism that equips cells with the ability to respond dramatically to external and internal insults. Consequently, apoptosis must be tightly connected to a variety of signals that transduce information on the status of the cell and its environment (78) . In human cells, apoptosis involves a large number of factors, including transcriptional regulators, transmembrane receptors, cytoplasmic mediators, adaptors, and caspases. Al-ternative splicing plays a major role in the control of apoptosis (78, 82, 93) . In many cases, alternative splicing programs the synthesis of proteins with different and sometimes opposing functions in apoptosis. This contribution affects all categories of apoptotic factors (78) . For example, the production of soluble forms of Fas and FasL can have an antiapoptotic function (4, 11) . Many members of the Bcl-2 family of proteins are also subject to splicing regulation, with Bcl-x possibly representing the best-documented case. The Bcl-x L splice isoform is produced through the use of a specific 5Ј splice site in exon 2 (Fig.  1A) . One manner by which Bcl-x L exerts its antiapoptotic activity is by binding to and inhibiting proapoptotic BH3 proteins such as Bad or Bax (18) . In contrast, Bcl-x S displays proapoptotic activity and is derived from the use of a 5Ј splice site located 189 nucleotides (nt) upstream from the x L site. Bcl-x S forms active homodimers and heterodimers with proapoptotic Bcl-2 family members (51). Alternatively, Bcl-x S can heterodimerize with antiapoptotic Bcl-2 family members such as Bcl-x L , rendering them inactive (15, 51) .
Despite the anticipated coupling between signal transduction events and alternative splicing decisions in apoptotic genes, there are only a few cases of this type of cross talk that have been reported. Activation of Fas at the membrane changes the alternative splicing of caspase 9 and Bcl-x (13, 14) . It turns out that Fas activation and a variety of other stimuli (5, 19, 31, 37, 52, 62, 71) promote the production of ceramide, a regulator of stress responses and growth pathways. Ceramide activates protein phosphatase PP1, which can dephosphorylate SR proteins (13) . Two cis-acting elements (CRCE1 and CRCE2) are necessary for the ceramide-induced accumulation of Bcl-x S in A549 cells (Fig. 1B) (57) . CRCE1 is bound by the U2-associated spliceosomal complex protein SAP155 (56), which is a substrate for PP1/PP2A phosphatases (80) . SAdenosylmethionine and its metabolite 5Ј methylthioadenosine also increase PP1 expression and Bcl-x S production in HepG2 and 293 cells (94) . A role for SR protein in Bcl-x splicing regulation may also be predicted based on the effect of an inhibitor of the SR protein kinase topoisomerase I (68) . The ratio of the Bcl-x isoforms is also affected by growth factors, including interleukin-1␣ (69), interleukin-6, and granulocytemacrophage colony-stimulating factor (50) . Tetradecanoyl phorbol acetate (TPA) can also affect the alternative splicing of Bcl-x in an apparent PKC-dependent manner (50) . A large intronic region immediately downstream from the Bcl-x L 5Ј splice site (Fig. 1B) has been linked to the effects of TPA and cytokines (50) . Very recently, phosphorylation of Sam68 by Fyn was shown to stimulate Bcl-x S usage in HEK293 cells (63) . The same study reported that hnRNP A1 can cooperate with Sam68 but that ASF/SF2 antagonizes the activity of Sam68 on Bcl-x splicing.
Also interesting is the observation that glucocorticoids activate transcription of Bcl-x from only one of five mouse promoters (92) . Mouse promoter P4 favors the production of the Bcl-x L splice isoforms (66) , whereas human promoter 1 displays this characteristic in human hepatoma cells (94) . Thus, transcriptional events can also determine the balance of proand antiapoptotic Bcl-x isoforms.
Given the crucial role of Bcl-x in apoptosis and the ability of its pre-mRNA to respond to various classes of effectors, we have made efforts towards understanding regulatory aspects of Bcl-x splicing control. Our previous work uncovered an element bound by the hnRNP H protein that enforces the use of the upstream Bcl-x S 5Ј splice site (23) (Fig. 1B) . In addition, an enhancer element was located immediately upstream of the Bcl-x L 5Ј splice site (23) . Here, we report that staurosporine improves the production of the Bcl-x S isoform by interfering with a signaling pathway that is dependent on PKC. The impact of staurosporine on Bcl-x splicing is mediated through a region in exon 2 (SB1) that normally represses the production of Bcl-x S . While staurosporine lifts this repression in 293 cells, it is unable to do so in a variety of cancer cell lines. Our results therefore uncover a novel regulatory mechanism affecting the alternative splicing of Bcl-x. Alterations in this pathway may contribute to the greater resistance of cancer cells to apoptosisinducing agents.
MATERIALS AND METHODS
Cell culture. The 293 cells used in this study were the EcR-293 cell line (Invitrogen). EcR-293, HeLa, U373, and U-87 cells were maintained in Dulbecco's modified Eagle's medium (DMEM) containing 10% fetal bovine serum and 1% glutamine. PC-3 cells were maintained in Ham's F12 medium containing 10% fetal bovine serum and 1% glutamine. SKOV-3 cells were maintained in DMEM/F12 medium containing 10% fetal bovine serum and 1% glutamine. MCF7 cells were maintained in Eagle's minimal essential medium/Earle's balanced salt solution medium containing 10% fetal bovine serum, 1% glutamine, 1 mM sodium pyruvate, 0.1 mM nonessential amino acids and 0.01 mg/ml bovine insulin. HCT 116 cells were maintained in McCoy's 5a medium containing 10% fetal bovine serum and 1% glutamine. (57) . CRCE1 is bound by the U2 snRNP protein SAP155, and its knockdown increases the production of Bcl-x S (56). B2G is bound by hnRNP H and stimulates the production of Bcl-x S (23) . B3 enhances the use of the Bcl-x L 5Ј splice site (23) . The intron regulatory element (IRE) has been implicated in mediating the activity of growth factors and TPA on Bcl-x splicing in various cell lines (50) . The SB1 element was previously shown to decrease the production of the Bcl-x S isoform (23) , and its position is indicated. Sam68 and hnRNP A1 also contribute to Bcl-x splicing, but the cis-acting elements mediating these effects have not yet been mapped (63) .
hundred micromolar of z-VAD-fmk (Calbiochem) or the indicated concentrations of 5, 6-dichloro-1-␤-D-ribofuranosylbenzimidazole (DRB) (Calbiochem) or cycloheximide (Calbiochem) were added 1 h before addition of staurosporine. Analysis of splicing profiles of Bcl-x was done as described previously (23) . Axl splicing products were amplified with primers Axl-f (CCCCTGAGAACATTA GTGCT) and Axl-r (AGAGCCAAGATGAGGACACA) using the same procedure and conditions as for Bcl-x.
Plasmid constructs. The Bcl-x minigenes were constructed as described previously (23) . Portions of SB1 were amplified by PCR using the following primers: for fragment A, A-forw (ATGCTGCAGTCGAGCTTCAG) and A-rev (CATC TGCAGAACCACCAGC); for fragment B, B-forw (ATGCTGCAGAACCAG AGAC) and B-rev (CATCTGCAGCTCAGTCCTG); and for fragment C, Cforw (ATGCTGCAGACTTTCTCTC) and C-rev (TATCTGCAGGGGCTGTC TG). Each PCR product was digested with PstI and gel purified. They were then ligated into Dup51 previously digested with NsiI. The plasmid constructs were verified by enzymatic digestion and sequencing. The pCMV-E1a plasmid has been described previously. The E1a minigene was constructed by digesting pCMVE1a (95) with PstI, blunting, and then digesting with XbaI. The E1a fragment was gel purified and inserted in pcDNA3.1ϩ digested with EcoRV and XbaI. Fragments B and C of SB1 were then inserted into the blunted EcoRI site.
Transfection of 293 cells. Cells (2 ϫ 10 5 ) were plated in 35-mm 2 wells. Fortyeight hours later, 0.05 g of DNA and 4 l of polyethyleneimine (1 g/l) were incubated for 15 min in 200 l (final volume) of Opti-MEM before being added to the wells, which contained 500 l of DMEM. Four hours later, 1.5 ml of DMEM was added to each well. At 24 hours posttransfection, the medium was changed and 50 nM of staurosporine was added where indicated. Cells were harvested 18 h later, and RNA was extracted using TRIzol (Invitrogen). Analysis of splicing profiles of the minigenes by RT-PCR was done as previously described (23) . Visualization and analysis of amplified products for Bcl-x were done using the LabChip HT DNA assay on an automated microfluidic station (Caliper, Hopkinton, MA).
RESULTS

Staurosporine modifies
Bcl-x pre-mRNA splicing in 293 cells. In order to identify signaling pathways that impinge on the control of splice site selection of Bcl-x, we tested whether staurosporine, a general kinase inhibitor and inducer of apoptosis (26, 88, 97) , could alter the relative abundances of the Bcl-x S and Bcl-x L splice isoforms in different cell lines. Staurosporine was applied to the adenovirus-transformed cell line 293 and six cell lines derived from a variety of cancers (U373, HeLa, SKOV-3, U-87, MCF7, and HCT 116). After 18 h of incubation with 25 nM of staurosporine, the relative levels of endogenous Bcl-x L and Bcl-x S mRNAs were estimated by RT-PCR from total RNA (Fig. 1A) . As expected, Bcl-x L was the predominant form found in all mock-treated cells ( Fig. 2A) . Staurosporine had no significant effect on the relative abundances of the Bcl-x L and Bcl-x S isoforms, except in 293 cells, where it drastically decreased the ratio of Bcl-x L to Bcl-x S .
The impact of staurosporine in 293 cells was dose dependent (Fig. 2B ). Because our staurosporine stock was dissolved in dimethyl sulfoxide (DMSO) and DMSO can affect alternative splicing (10), we tested the impact of DMSO on the relative abundances of Bcl-x isoforms. At its highest concentration, which was twice the concentration present in the 150 nM staurosporine solution, DMSO affected the Bcl-x splice isoform ratio by less than 2-fold, whereas staurosporine usually shifted splicing by 10-fold (Fig. 2B , compare lane 8 with lane 7). The effect of staurosporine on Bcl-x splicing was visible after 12 h of incubation (Fig. 2C) . Raising the concentration of staurosporine and/or increasing the incubation time did not change the Bcl-x isoform ratio in the cancer cell lines even though morphological changes characteristic of apoptosis (membrane blebbing, cell shrinkage, and formation of apoptotic bodies) were apparent in a majority of cells in all cell lines (data not shown). Thus, the signaling pathways that determine the relative abundances of Bcl-x mRNA isoforms in cancer cell lines are resistant to staurosporine.
Although the amplitude of the effect of staurosporine on the Bcl-x isoform ratio suggests that the drug might influence Bcl-x alternative splicing, it is possible that staurosporine differentially affects the stability of the Bcl-x mRNAs. To address this question, we tested the impact of staurosporine after inhibiting transcription elongation with increasing concentrations of DRB (Fig. 2D) . Increasing concentrations of DRB antagonized the shift towards Bcl-x S . This result indicates that the staurosporine-induced decrease in the Bcl-x L /Bcl-x S ratio requires active transcription, suggesting that differential stability of the Bcl-x mRNA isoforms does not make a major contribution to the shift induced by staurosporine.
To test whether the shift in the alternative splicing of Bcl-x requires de novo protein synthesis, we tested the impact of staurosporine in the presence of the protein synthesis inhibitor cycloheximide. When applied alone, cycloheximide stimulated Bcl-x S splicing, and this effect was dose-dependent (Fig. 2E , lanes 3, 5, and 7), possibly due to its activation of mitogenactivated and stress-activated kinases (98) . Adding staurosporine at 1 hour after the treatment with cycloheximide resulted in a marked increase in the Bcl-x S product at all concentrations of cycloheximide (Fig. 2E, lanes 4, 6, and 8 ). Because cycloheximide did not antagonize the staurosporine-induced shift to Bcl-x S , splicing modulation by staurosporine is likely achieved through the posttranslational modification of splicing factors rather than through the expression of newly synthesized regulatory proteins.
The effect of staurosporine on Bcl-x splicing is caspase independent. Staurosporine can induce apoptosis through caspase-dependent or caspase-independent pathways (6, 86, 97) . Therefore, some of the changes in the alternative splicing of Bcl-x may be due to caspase-dependent alterations in the integrity of splicing regulatory components. Indeed, many RNA binding proteins and spliceosome components can be cleaved during apoptosis (12, 20, 22) . To test whether the shift in Bcl-x splicing was dependent on the activation of caspases, 293 cells were pretreated with z-VAD-fmk, a general caspase inhibitor known to inhibit apoptosis caused by staurosporine in a variety of cell lines (26, 97) . Activation and inhibition of caspases by z-VAD-fmk were verified using the poly(ADPribose) polymerase (PARP) cleavage assay (44) . In comparison to vinorelbine, staurosporine did not elicit PARP cleavage, and z-VAD-fmk prevented PARP cleavage induced by vinorelbine (Fig. 3A) . Moreover, z-VAD-fmk had no basal effect on Bcl-x splicing and did not antagonize the staurosporine-mediated switch towards Bcl-x S (Fig. 3B, lanes 3 and 4) . Therefore, caspase activation does not contribute to the staurosporinemediated change in Bcl-x splicing.
PKC inhibition shifts Bcl-x splicing. Staurosporine can inhibit a broad spectrum of kinases such as PKC, PKG, PKA, CaM kinase, myosin light chain kinases, and others (75) . However, it has greater potency against PKC (50% inhibitory concentration [IC 50 ] ϭ 700 pM; K i ϭ 19 nM). To investigate whether staurosporine might act on Bcl-x splicing by inactivating PKC, we tested the specific PKC inhibitor Gö6976 (IC 50 ϭ VOL. 27, 2007 CONTROL OF Bcl-x SPLICING BY PKC 8433 7.9 nM; K i ϭ 2.8 nM) (39, 55) . The incubation of 293 cells for 18 h with Gö6976 promoted an increase in the Bcl-x S product, as seen with staurosporine (Fig. 3C, lanes 1 to 6) . Inhibiting PKA or PKG using H-89 (45 nM; K i ϭ 48 nM) or DT-3 (45 nM; K i ϭ 25 nM), respectively, only minimally increased the production of Bcl-x S in 293 cells (data not shown). Thus, the impact of staurosporine on the alternative splicing of Bcl-x in 293 cells is likely to be mediated mostly through the PKC pathway. Other observations are relevant to the role of PKC in Bcl-x splicing. First, DMSO can induce PKC-mediated apoptosis (25), possibly explaining the small effect of DMSO on Bcl-x splicing (Fig. 2B, lane 8) . Second, calphostin C, a highly specific inhibitor of PKC (IC 50 ϭ 50 nM) (38) , also increased the production of Bcl-x S in 293 cells (Fig. 3D) . Third, tamoxifen, which has been reported to inhibit PKC (61) Modulation of Bcl-x and Axl splicing by staurosporine does not occur in cancer cell lines. Notably, staurosporine and Gö6976 did not improve the production of Bcl-x S in the cancer cell lines HCT 116, HeLa, and PC-3 (Fig. 3C, lanes 7 to 24) . The PKC pathway is known to be abnormally regulated in many cancer cell lines (40) , which may explain why the alter- To identify other alternative splicing events that might be controlled by PKC, we tested the impact of staurosporine on other pre-mRNA substrates expressed in 293 cells. First, we tested the production of isoforms produced from the adenovirus E1a pre-mRNA, a gene whose expression contributes to the transformed state of 293 cells. Like Bcl-x, E1a uses alternative 5Ј splice site usage to produce a variety of isoforms (13S, 12S, and 9S mRNAs). Staurosporine did not affect the alternative splicing of E1a (Fig. 4A) . Thus, the impact of staurosporine appears not to involve a factor that controls alternative 5Ј splice site selection in a global manner.
Next, we tested the impact of staurosporine on the production of mRNA isoforms produced from a selection of apoptotic genes expressed in 293 cells. While most of the splicing units tested were not affected by staurosporine, the alternative splicing of the receptor tyrosine kinase Axl was significantly affected (Fig. 4B, lanes 3 and 4) . The skipping of an alternative exon in Axl was also stimulated by the PKC inhibitor Gö6976 (Fig. 4C,  lane 3) . Although aberrant expression of Axl has been linked to cancer (28, 90) , the function of the short isoform whose abundance is enhanced by staurosporine is currently unknown. Thus, the PKC pathway likely controls the alternative splicing of a subset of pre-mRNAs in 293 cells. As was the case with Bcl-x, staurosporine did not stimulate exon skipping of Axl in the HCT116, HeLa and PC-3 cancer cell lines (Fig. 4C) . Staurosporine mediates its activity through an element in Bcl-x exon 2. If the PKC-dependent effect of staurosporine on Bcl-x splicing is specific and not due to general splicing deregulation, this effect may be exerted through a protein that binds to a sequence element in the Bcl-x pre-mRNA. To identify regions in the Bcl-x pre-mRNA that may be necessary for the activity of staurosporine, we compared the splicing ratios of transcripts derived from Bcl-x minigenes (Fig. 5A ). X2 contains exon 2 and 1.2 kb of downstream intron sequence with exon 3 and neighboring upstream intron sequences (23) . X2.13 is identical to X2 except that it lacks the first half of exon 2. Following transfection of the Bcl-x minigenes in 293 cells, RT-PCR analysis indicated that transcripts from X2 were spliced more efficiently to the Bcl-x L 5Ј splice site than those expressed from X2.13 (Fig. 5B , compare lane 1 with lane 3 and the accompanying graph). Thus, the 361-nt region forming the first half of exon 2, dubbed SB1, behaves as an inhibitor of the Bcl-x S 5Ј splice site. When the analysis was performed with transfected cells treated with staurosporine, we observed a shift towards Bcl-x S for transcripts derived from X2, thereby reproducing the impact of staurosporine on endogenous Bcl-x transcripts (Fig. 5B, lane 2) . In contrast, the same treatment had a much-reduced impact on the ratio of isoforms produced from X2.13 (lane 4). These results indicate that staurosporine can lift the basal repression of the Bcl-x S 5Ј splice site that is provided by SB1. We also tested mutated derivatives of X2 and X2.13 (X2-W and X2.13-W [ Fig. 5A] ) that produce more of the Bcl-x L isoform. In these cases, the repressor activity of SB1 was also apparent (Fig. 5B , compare lane 5 with lane 7 and the accompanying graph), and the production of Bcl-x S was stimulated by staurosporine in an SB1-dependent manner (Fig. 5B,  lanes 6 and 8) .
Although staurosporine did not promote an increase in the level of the Bcl-x S mRNA in cancer cells ( Fig. 2A) , we transfected the X2 and X2.13 minigenes in HeLa cells to determine whether the SB1 element had any activity in this cell line. Notably, the use of the Bcl-x S 5Ј splice site was stronger in the absence of the SB1 element (Fig. 5C) , confirming a previous observation made with HeLa cells (23) and indicating that the SB1 element actively represses the x S donor splice site. This result suggests that the SB1 element functions in cancer cells but that staurosporine is unable to lift the repression.
To confirm the role of SB1 and the neutralization of its activity by staurosporine, we asked whether portions of SB1 were capable of directing splicing decisions in different contexts. As shown in Fig. 6A , we inserted three partially overlapping portions of SB1 into the first exon of Dup51, a model splicing unit derived from duplicated human ␤-globin regions (21) . Following transfection in 293 cells and RT-PCR analysis, we observed that all portions of SB1 enhanced the skipping of the central exon (Fig. 6B) , with fragment C (159 nt) having the . When transfected cells were treated with staurosporine, the alternative splicing of Dup51 and of derivatives containing fragments A and B was not significantly affected (Fig. 6B, lanes 2, 4, and 6 ). In contrast, staurosporine neutralized the exon-skipping activity of fragment C (lane 8).
We also tested the activities of portions B and C of SB1 when they were inserted at an upstream position in an adenovirus E1a minigene (95) . In this case, only fragment B influenced alternative splicing by improving the inclusion of a central exon that produces the 10S isoform (Fig. 6C, lane 3) . Staurosporine enhanced the inclusion of this exon in a fragment B-dependent manner (lane 4). Thus, fragment C displayed splicing modulatory activity in Dup51 and mediated the staurosporine splicing shift, while this behavior was a characteristic of fragment B in E1a. Although fragments B and C are overlapping, our results suggest that the SB1 element is complex and that the activities of distinct portions of SB1 are sensitive to the context in which they are tested. Nevertheless, it is clear that portions of SB1 can modulate splice site selection in an heterologous manner and that responsiveness to staurosporine can be transferred to other pre-mRNAs. Thus, our results suggest that SB1 is bound by factors whose activity is connected to the PKC pathway.
DISCUSSION
PKC-dependent control of Bcl-x splicing in 293 cells. As can be expected for a gene that produces isoforms with antagonistic functions in apoptosis, the alternative splicing of Bcl-x is highly regulated, and several sequence elements contribute to its splicing control. Among these are sequences that may couple splicing decisions with the transduction of signals initiated by growth factors and ceramide (50, 57) . Although staurosporine can downregulate Bcl-x L levels in a few cell lines, a corresponding increase in Bcl-x S was not observed previously (26) . Our study indicates that staurosporine stimulates the production of the proapoptotic Bcl-x S isoform in 293 cells. Because pretreatment with the transcriptional inhibitor DRB prevents the increase in Bcl-x S seen with staurosporine, this drug appears to act on the alternative splicing of Bcl-x rather than on the differential stabilities of mRNA isoforms. Moreover, the impact of staurosporine is not caused through protein cleavage, since incubation with a general inhibitor of caspases did not prevent the shift in Bcl-x splicing.
The fact that the translational inhibitor cycloheximide did not antagonize the staurosporine-induced splicing shift suggests that signaling events are responsible for the impact of staurosporine on Bcl-x splicing. Staurosporine is a known PKC inhibitor. Consistent with the possibility that staurosporine alters Bcl-x splicing in 293 cells through repression of PKC, we observed that the PKC␣/PKC␤/PKC inhibitor Gö6976 and the highly specific PKC inhibitor calphostatin C can mimic the staurosporine-mediated increase in Bcl-x S in 293 cells. This situation is similar to the PKC/Ras-induced shift in alternative splicing of CD44 (41), but it contrasts with the alternative splicing of CD45 where the PKC/Ras-dependent splicing switch is blocked by cycloheximide, indicating that one or several proteins must be made following activation (53) .
The involvement of PKC in the control of Bcl-x splicing is not totally surprising. On the one hand, suppression of PKC is associated with the induction of apoptosis, which at least in some cases is accompanied by a reduction in the expression of Bcl-x L (26, 33, 48, 77) . On the other hand, ceramide, which promotes Bcl-x S usage in A549 cells, is known to repress PKC␣ (46) and to induce the ceramide-activated protein phosphatase PP1 (14) . However, the elements that have been associated with the response to ceramide are distinct from SB1 (57) . Nevertheless, because the role of SB1 in the response to ceramide has not been examined, it is possible that part of the PKC-dependent impact of ceramide is exerted through SB1.
An exon element mediates the PKC-dependent repression of Bcl-x S . We have linked the effect of staurosporine on Bcl-x splicing to a 361-nt element (SB1) situated 187 nt upstream of the Bcl-x S 5Ј splice site. The SB1 element displays basal repressor activity, because its removal stimulates the use of the Bcl-x S 5Ј splice site in transfection assays performed with 293 and HeLa cells. Thus, 293 and HeLa cells likely contain a factor that mediates the repressor activity of the SB1 element. This interpretation is consistent with the observation that transfecting large amounts of Bcl-x plasmid in 293 cells increased the relative level of Bcl-x S and antagonized our ability to detect the SB1-dependent effect (data not shown). However, as suggested by testing SB1 fragments in a heterologous context, the mechanism of action of SB1 is probably more complex, because exon skipping in Dup51 was promoted by different portions of SB1 whereas a subregion of SB1 (fragment B) elicited exon inclusion in E1a.
In the absence of SB1, splicing to Bcl-x S was stronger and was not further stimulated by staurosporine. Thus, staurosporine appears to neutralize the repressor activity mediated by the SB1 element in 293 cells. In a heterologous context, the portions of SB1 that conferred a response to staurosporine stimulated the inclusion of downstream exons, a situation that is difficult to reconcile with a simple derepression model. Moreover, the portions of SB1 that conferred responsiveness to staurosporine varied with different pre-mRNAs. A more exhaustive mutational analysis of the SB1 element and the iden- Given the role of PKC in the activity of SB1 and the lack of a requirement for new protein synthesis, our results suggest that a phosphorylated protein may be essential for the activity of SB1. The inhibition of PKC may shift the equilibrium towards a dephosphorylated form that may not be binding to SB1 or that may be incapable of sustaining interactions with other proteins involved in the repression of the 5Ј splice site Bcl-x S . We have been unable to reproduce in vitro the impact of SB1 on Bcl-x splicing using 293 extracts, a situation that may also point to a particularly labile phosphorylation event that is lost during extract preparation. The identity of this trans-acting factor therefore remains to be determined. Phosphorylationdependent binding has been observed for many RNA binding proteins, including SR proteins (30, 34, 42, 70, 87) . Interestingly, PKC can interact with PSF, hnRNP A3, p68 RNA helicase, and hnRNP L (72) . The alternative splicing of CD45 during T-cell activation has also implicated both PKC and hnRNP L, with the latter protein interacting directly with sequences in the regulated exons (53, 74) . Knocking down hnRNP L in HeLa cells did not affect Bcl-x splicing (data not shown). Sam68 has recently been shown to improve the production of the Bcl-x S isoform in HEK293 cells (63) . Although the binding site for Sam68 in Bcl-x has not been mapped, Sam68 may counteract the activity of the repressor that binds to SB1.
We have observed that staurosporine and Gö6976 can also affect the alternative splicing of Axl, a gene encoding a protein kinase receptor whose expression is altered in cancer cells (32, 81) . The larger isoform of Axl protects cells against apoptosis when bound to its receptor Gas6 (47, 79) , but the function of the smaller isoform is unknown. Thus, the PKC signaling pathway is involved in modulating the splicing of several premRNAs, but it is unclear whether all PKC-dependent splicing shifts converge on the same splicing regulatory factor(s). Comparing the sequences shared by fragments B and C of exon 2 in Bcl-x with the equivalent region in Axl revealed common stretches of CU-rich sequences. A mutational approach combined with swapping experiments should help determine if the staurosporine-induced splicing shift of Bcl-x and Axl is mediated by functionally similar elements.
Altered PKC pathway in cancer cells. Of the eight cell lines that were treated with staurosporine, a shift towards the proapoptotic Bcl-x S isoform was observed only in 293 cells. Likewise, the alternative splicing of Axl was modulated by staurosporine in 293 cells but not in the cancer cell lines. It is unlikely that this selectivity reflects an inability of the drug to reach sufficiently high intracellular concentrations in cancer cells, since staurosporine induced a phenotype characteristic of apoptosis in all cell lines. Moreover, the PKC inhibitor Gö6976 was also unable to promote a splicing switch in the cancer cell lines. Thus, the PKC pathway in the cancer cell lines tested either is inactive or is resistant to the action of inhibitors. We favor the latter explanation because activation of the PKC␣/PKC␤ isozymes has been linked to malignancy (40) . In addition, the SB1 element that represses the Bcl-x S 5Ј splice site is functional in HeLa cells. The molecular basis for the resistance of the PKC pathway to staurosporine and to Gö6976 remains unclear. Different PKC isoforms and isozymes may be expressed in cancer cells (1, 43, 91) . These PKC variants may be less sensitive to inhibitors, or they may not phosphorylate the proteins that relay repression through the SB1 element in 293 cells. Alternatively, PKC activity may be more susceptible to inhibition in 293 cells. Consistent with this view, the expression of the adenovirus E1a gene can promote a relocalization of PKC to membranes (83) .
Based on these observations, we are now testing the impact of a battery of chemotherapeutic agents on the alternative splicing of Bcl-x and other genes in a variety of cell lines. In addition to helping in uncovering networks of splicing regulation, this approach may reveal cancer-specific differences in abilities to couple signaling events with splicing decisions.
